The Latest SPAC News and Rumors: September 15, 2021


The Latest SPAC News and Rumors: September 15, 2021

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Carousell becomes Singapore’s newest unicorn, Acorns names former Amazon executive as president, and Anghami partners with Amazon Prime

Online Marketplace Carousell Is Singapore’s Newest Unicorn

Online classifieds marketplace Carousell Pte became Singapore’s latest tech unicorn, raising funds at a $1.1 billion valuation as Southeast Asia’s e-commerce startups benefit from the pandemic and related lockdowns, according to Bloomberg.

The company got $100 million in a round led by South Korean private equity firm STIC Investments.

Carousell has weighed a U.S. listing via a merger with a blank-check company, people with knowledge of the matter said in June.


Acorns Names Amazon Alum David Hijirida as President Ahead of IPO

Acorns Grow Inc. hired former Inc. executive David Hijirida as its president, as the savings and investing startup prepares to go public by merging with a blank-check company.

On May 27, Acorns entered into a definitive agreement to combine with Pioneer Merger Corp. (NASDAQ:PACX).


Amazon Prime and Anghami Collaborate in Saudi Arabia and United Arab Emirates with Anghami Plus

Amazon and Anghami have today announced that Amazon Prime members in Saudi Arabia and the UAE can enjoy an exclusive six-months free offer on Anghami Plus, Anghami’s premium paid tier, with their Prime membership.

Prime members in Saudi Arabia and the UAE will receive a free six-month subscription to Anghami Plus, followed by 50% off the subscription fee for the next six months.

On March 3, Anghami entered into a definitive agreement to combine with Vistas Media (NASDAQ:VMAC).


SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza  

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of enrollment in its Phase 2a clinical trial evaluating the safety and efficacy of SAB-176 in a challenge study.

SAB-176 is a novel anti-influenza human immunotherapy designed to address the limitations of current treatments for moderate to severe seasonal influenza.

On June 22, SAB announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP).